Linsitinib (OSI-906)

Catalog No.S1091

Linsitinib (OSI-906) Chemical Structure

Molecular Weight(MW): 421.49

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 720 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Cancer Res 2013 73, 834-843. Linsitinib (OSI-906) purchased from Selleck.

    OSI-906 prevents the emergence and inhibits growth of established hormone-indendent tumors . A and B, MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release E2 pellets. Mice with no tumors (A) or bearing tumors ≥ 150 mm3 (B) were randomized to vehicle or OSI-906 (50 mg/kg/day, per os) for 6 weeks. Data are presented as number of tumors formed ; , P = 0.02, Fisher's exact test (A) , or mean tumor volume ± SEM; P < 0.05 versus vehicle, 2-way ANOVA (B). C, tumor-bearing mice from (A) were treated with vehicle or OSI-906 for 3 days. Xenografts were harvested 4 hours after the last dose. Tumor lysates were precipitated with a p-Tyr antibody; p-Tyr pull- downs and tumor lysates were analyzed by immunoblot with the indicated antibodies. D, tumor-bearing mice were imaged before and 4 hours after the initial dose of OSI- 906 by [18 F]FDG -PET. Images from a representative mouse show [18 F]FDG uptake pre- and post–OSI-906 (T-tumor ). Quantification is shown at the bottom.  , P < 0.0001, 2-way ANOVA .

    Cancer Res 2011 71, 6773-84. Linsitinib (OSI-906) purchased from Selleck.

  • (A) MHM cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) or Erlotinib (10 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. EGFR immuno-precipitates were probed with anti-phospho tyrosine antibody. In lanes marked “Serum Starved”, MHM cells were serum starved for 24 hours and stimulated with EGF (10 ng/ml) for 10 minutes. Lysates were collected and immunoblotted with indicated antibodies. (B) OS cell lines and primary OS cells were treated with CP (10 μM) alone, OSI-906 (5 μM) alone or with CP in combination with OSI-906 for 48 hours and whole cell lysates were immunoblotted with the indicated antibodies. (C) MHM and S4 (CP resistant MHM derivatives) cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. (D) IGF1 and IGF2 mRNA levels in untreated cells and cells treated with 10 μM CP for 48 hours were determined by qRT-PCR. The level of each mRNA transcript in untreated cells was considered “1.0” and all the other values were plotted relative to it. Shown are the mean results of three experiments, bars, Standard error (SE).

    Oncotarget, 2016, 7(19):27511-26. Linsitinib (OSI-906) purchased from Selleck.

     

    (A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.

    Linsitinib (OSI-906) purchased from Selleck.

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk M2PR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nHZ2lEPTB;MD6wNlgxPiEQvF2= NX;ZfIVGW0GQR1XS
KS-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLYTWM2OD1yLkCzPFM2KM7:TR?= NUH4ZodoW0GQR1XS
TE-11 M4fkbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\MbWFJUUN3ME2wMlA4QDJ{IN88US=> NX7oSodUW0GQR1XS
EW-1 MlvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHG2O5VKSzVyPUCuNFg2QDVizszN MXHTRW5ITVJ?
HMV-II NWW4T|ZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTBwMEi4OFYh|ryP MkCxV2FPT0WU
COLO-205 M4PyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvjTWM2OD1yLkGwOFU1KM7:TR?= MUTTRW5ITVJ?
ES1 NFTUVXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwMUC2PVYh|ryP MoWzV2FPT0WU
GDM-1 NHKwS2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;uUVhoUUN3ME2wMlE{Pjd{IN88US=> MlXkV2FPT0WU
ML-2 MkPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLGTWM2OD1yLkG1PFk3KM7:TR?= NH;EN5FUSU6JRWK=
Saos-2 NImwcZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1KyV2lEPTB;MD6xOlUzPiEQvF2= NYGxXFFWW0GQR1XS
NCI-H1355 M2DwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnYT3ZYUUN3ME2wMlE5OTN3IN88US=> M1HRenNCVkeHUh?=
G-401 MmPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkT0TWM2OD1yLkG4NlMh|ryP Mo\LV2FPT0WU
EW-16 M1:5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoC1TWM2OD1yLkG4O|c4KM7:TR?= NVHYe29WW0GQR1XS
EW-7 MoT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[ydpZtUUN3ME2wMlE5QDhzIN88US=> MUXTRW5ITVJ?
NCI-H727 NXr6bpF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13CTGlEPTB;MD6xPVc6PCEQvF2= MX7TRW5ITVJ?
LCLC-97TM1 NWWwVGlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnuWHJPUUN3ME2wMlIxQTV3IN88US=> MkO3V2FPT0WU
NCI-H650 NEPS[2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXoTWM2OD1yLkKxN|g1KM7:TR?= M4D6enNCVkeHUh?=
NCI-H2122 M4\Memdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwMkOyPVkh|ryP NVLKbnV6W0GQR1XS
SK-N-DZ M2nURmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGOzSphKSzVyPUCuNlM3QThizszN M3q5c3NCVkeHUh?=
HT-29 NUDHXXBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HFcGlEPTB;MD6yOFI1QCEQvF2= M{fL[3NCVkeHUh?=
LB771-HNC NEHHVWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTBwMkW5NVUh|ryP MoX3V2FPT0WU
HT-144 NIfQfHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LHVGlEPTB;MD6yOlE6OSEQvF2= NG\Xd|ZUSU6JRWK=
LAN-6 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnab25KSzVyPUCuNlY{PDhizszN M1XyXHNCVkeHUh?=
EW-18 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwMkewNFEh|ryP NIr5ZnBUSU6JRWK=
LS-1034 NYXlU|I6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjWTWM2OD1yLkK3NVMzKM7:TR?= NFvyTJRUSU6JRWK=
EW-11 NVriUJdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4W0OGlEPTB;MD6yPFQ{OiEQvF2= M2SyUXNCVkeHUh?=
SNU-C1 NWjUS|ZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrWRpRWUUN3ME2wMlI6OzF|IN88US=> NWrhT3A3W0GQR1XS
RS4-11 Mlu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPaTWM2OD1yLkOzO|U5KM7:TR?= M1vDbnNCVkeHUh?=
ES4 MknUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{P1W2lEPTB;MD60NVA{QCEQvF2= NH\4TJBUSU6JRWK=
COLO-320-HSR NVT3Wo95T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXvOJpkUUN3ME2wMlQyOzZ6IN88US=> NEW3U4lUSU6JRWK=
NB10 MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEG1[YxKSzVyPUCuOFU1OzdizszN M3Ly[HNCVkeHUh?=
BFTC-905 M3ftU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwNE[3OVgh|ryP Mlu1V2FPT0WU
A375 NIHJU4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwNEe2NVch|ryP NWK4VHVFW0GQR1XS
SJRH30 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHP[m9xUUN3ME2wMlUxQDJ{IN88US=> M3y1PHNCVkeHUh?=
NOS-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWr3V4lKUUN3ME2wMlUzOjZ5IN88US=> NHnEb2VUSU6JRWK=
SIG-M5 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLSTWM2OD1yLkWzOVU4KM7:TR?= MlewV2FPT0WU
DOK NED6WIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTBwNUW2JO69VQ>? M3jnXXNCVkeHUh?=
NB69 NFvjSXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHuZYNKSzVyPUCuOVgzPTdizszN NXHxTlFLW0GQR1XS
SK-NEP-1 MlTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Ty[2lEPTB;MD62NFI{PiEQvF2= NVPOOHBUW0GQR1XS
SK-MM-2 NV7Ec3d{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHK3d|VKSzVyPUCuOlU1QTFizszN Ml73V2FPT0WU
NCI-H358 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TwV2lEPTB;MD62O|A5OiEQvF2= M13k[nNCVkeHUh?=
RH-1 NEPjW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjNNYIyUUN3ME2wMlc1QDV7IN88US=> M37pNnNCVkeHUh?=
NH-12 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjpT2RKSzVyPUCuO|YxPDZizszN NYL4cJVwW0GQR1XS
TE-12 NULrN|JOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XOZ2lEPTB;MD63OlQ5PiEQvF2= NFXMW4tUSU6JRWK=
COLO-668 NFnXfY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwOES2OlYh|ryP MUnTRW5ITVJ?
PANC-08-13 MnW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjJOplKSzVyPUCuPFY{PzdizszN NVzEenNXW0GQR1XS
HCC2998 NUDubnA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwOEiyOlMh|ryP NVzFRoJ4W0GQR1XS
ABC-1 MnXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MortTWM2OD1yLkmwN|UzKM7:TR?= M3jrRXNCVkeHUh?=
ES6 M4TuSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIP3SZdKSzVyPUCuPVExPjZizszN MWDTRW5ITVJ?
SNU-387 NHG1NFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPhe2tKSzVyPUCuPVk{QTNizszN MWfTRW5ITVJ?
CMK M2TEfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PF[WlEPTB;MD65PVkzQSEQvF2= MU\TRW5ITVJ?
SJSA-1 NVHLOXB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlu1TWM2OD1zLkCzOlU{KM7:TR?= MoXWV2FPT0WU
SIMA M37Ib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mom4TWM2OD1zLkC2PFI2KM7:TR?= M3LmUXNCVkeHUh?=
ES3 NUWxSplXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7SPWFlUUN3ME2xMlEzOjl5IN88US=> MUPTRW5ITVJ?
IGROV-1 NXXqVoNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PFXWlEPTB;MT6xOVQ1PCEQvF2= MV7TRW5ITVJ?
MEL-JUSO M373SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPLTWM2OD1zLkG1O|U6KM7:TR?= M2fsUXNCVkeHUh?=
T84 NU\KNolzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTSTWM2OD1zLkKwPVE1KM7:TR?= NF7wNXlUSU6JRWK=
CAL-85-1 NFmyUVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;xTWM2OD1zLkKzNVM5KM7:TR?= MYTTRW5ITVJ?
RD MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlT5TWM2OD1zLkK2OFU2KM7:TR?= MlmzV2FPT0WU
TE-8 NH\lcYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn4O2FbUUN3ME2xMlMyPDZ{IN88US=> MlzRV2FPT0WU
L-363 NVf2NZRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnziTWM2OD1zLkO0NlA5KM7:TR?= MYLTRW5ITVJ?
EKVX MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\jRmlEPTB;MT6zOFU3QCEQvF2= MX;TRW5ITVJ?
SK-MEL-3 NWjT[otbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTFwNEi1OVYh|ryP MoHsV2FPT0WU
TGBC24TKB NW\acXJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYD3OGNYUUN3ME2xMlUxOTl|IN88US=> M4HQNXNCVkeHUh?=
NCI-H1770 MlHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTFwNUGxNVMh|ryP MoXuV2FPT0WU
HuH-7 NV32XFZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHSTGlKSzVyPUGuOlAxQThizszN NWfKSGhuW0GQR1XS
HL-60 MmfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfQS3NzUUN3ME2xMlY3QTJ6IN88US=> NG\S[pRUSU6JRWK=
TE-1 MmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTIbnI6UUN3ME2xMlcxQTR3IN88US=> MkS1V2FPT0WU
LC-2-ad MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTFwN{O4PFch|ryP NWToUYhFW0GQR1XS
LB647-SCLC MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIK2b5pKSzVyPUGuO|Y2QDNizszN MUfTRW5ITVJ?
NCI-H2171 M2\OPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTFwN{e3NVYh|ryP Ml;mV2FPT0WU
SK-PN-DW MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTFwOUGyPVgh|ryP MlXLV2FPT0WU
MC-IXC MnruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPLToZ7UUN3ME2xMlk5QThizszN M37TcnNCVkeHUh?=
LS-513 NWTLR2o4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17C[2lEPTB;Mj6wOVMxPSEQvF2= NGW5d4VUSU6JRWK=
EW-3 NXPRW4xRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[1TWM2OD1{LkC5PFQ1KM7:TR?= MlHiV2FPT0WU
OPM-2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfYTWM2OD1{LkGwNkDPxE1? MWHTRW5ITVJ?
LP-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJwMkW4NFch|ryP M{WzVHNCVkeHUh?=
LU-134-A M2r2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkftTWM2OD1{LkK3O{DPxE1? NGnoVmFUSU6JRWK=
CP66-MEL MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDmTGFKSzVyPUKuNlkxOTRizszN Mo\aV2FPT0WU
HCC1143 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTJwNEWzOlgh|ryP MVXTRW5ITVJ?
LOXIMVI M1XTVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nmTGlEPTB;Mj62NFIyKM7:TR?= NUfVfY1PW0GQR1XS
TE-10 M2qycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{C4WmlEPTB;Mj63NFg{QCEQvF2= NH72V3dUSU6JRWK=
NCI-H1882 NIXQ[nFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTJwN{WyNlch|ryP NWLRVIVVW0GQR1XS
CHP-126 MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXi5WVRNUUN3ME2yMlc3OzF5IN88US=> M{TCRXNCVkeHUh?=
NCI-H1623 M4e2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fETWlEPTB;Mj65NlAzPCEQvF2= M4PudnNCVkeHUh?=
GB-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfhXlRzUUN3ME2yMlk{PDB2IN88US=> M3XjZXNCVkeHUh?=
RCC10RGB M3rrT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJwOUWyPFEh|ryP NHLDUY9USU6JRWK=
NCI-H2141 NVyyOmE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnsTWM2OD1{Lkm2PFk3KM7:TR?= NGXNTGNUSU6JRWK=
GI-ME-N M363SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DWXWlEPTB;Mz6wNFU3PSEQvF2= M3HjOXNCVkeHUh?=
NCI-H526 MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPsTFdjUUN3ME2zMlA1ODh3IN88US=> M{jw[XNCVkeHUh?=
NCI-H747 NFXobJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTNwMES5PVIh|ryP MXrTRW5ITVJ?
SNU-423 M125cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHaTWM2OD1|LkKwN|E{KM7:TR?= M3PEU3NCVkeHUh?=
A427 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTyNFNKSzVyPUOuNlU3QTlizszN NXW0b3dlW0GQR1XS
CAL-12T NXTBWoY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnqcXZmUUN3ME2zMlQxPzF|IN88US=> M4HpdXNCVkeHUh?=
LU-99A MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Gy[mlEPTB;Mz60O|ExPSEQvF2= NU\PZ|lKW0GQR1XS
MS-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XwO2lEPTB;Mz61N|QzQSEQvF2= NVewWXR{W0GQR1XS
SK-LU-1 Ml\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTNwN{[yPVUh|ryP MonTV2FPT0WU
SW837 NX\tOnRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\lR|hKSzVyPUOuO|Y{OzNizszN NXmx[4NEW0GQR1XS
ES8 M1rEUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4m0SWlEPTB;Mz64N|g4PyEQvF2= MVTTRW5ITVJ?
MZ2-MEL MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTNwOUKwPFYh|ryP M4DZd3NCVkeHUh?=
TGW MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fkSGlEPTB;ND6wNVMyOSEQvF2= MUDTRW5ITVJ?
GP5d NUXJVoFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHsdIFKSzVyPUSuNFU{PjJizszN NWTrbXBvW0GQR1XS
BB49-HNC NFr0boJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTRwMUWyNVMh|ryP M3TYcnNCVkeHUh?=
NB13 Ml6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTRwMk[4PFch|ryP NWjW[oo5W0GQR1XS
NTERA-S-cl-D1 NGf4XmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTRwMki2NVUh|ryP M2HheHNCVkeHUh?=
NCI-H1648 M2LySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTNeFJ2UUN3ME20MlI6QDF7IN88US=> NVnwNm5nW0GQR1XS
LCLC-103H M3XqZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NImzOpJKSzVyPUSuN|IyQTVizszN NG\UfXdUSU6JRWK=
LS-411N MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTRwNES4PFUh|ryP NVLaTWQ2W0GQR1XS
NCI-H1092 Mme1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:zTWM2OD12LkS1Olg4KM7:TR?= M4LH[XNCVkeHUh?=
PANC-10-05 NYjuXpRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkH5TWM2OD12Lk[5PFQh|ryP MonkV2FPT0WU
DK-MG Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoX3TWM2OD12LkiwPVM{KM7:TR?= NILGW3ZUSU6JRWK=
OVCAR-5 NIDXdodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TIVmlEPTB;ND64NVIzPiEQvF2= M4rRRnNCVkeHUh?=
CAL-39 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXU[op7UUN3ME20Mlg4PjdizszN MkT1V2FPT0WU
TE-441-T NXjiOY4yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHhPJJKSzVyPUSuPVA2OzdizszN NFixd4VUSU6JRWK=
MOLT-16 M1KyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmr6TWM2OD12Lkm1NlU{KM7:TR?= MmTaV2FPT0WU
MCF7 NVn3PIE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTmfFFlUUN3ME21MlE1PTF5IN88US=> MnG0V2FPT0WU
CAPAN-1 NVHNO5RbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\DfZFrUUN3ME21MlI2PzB5IN88US=> NUm4XWRoW0GQR1XS
PSN1 Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3X4ZWlEPTB;NT6yO|I{PSEQvF2= M3HueHNCVkeHUh?=
NCI-H292 MlvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPaendKSzVyPUWuN|AxPDRizszN MYDTRW5ITVJ?
CPC-N MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HhOWlEPTB;NT6zPVQyQSEQvF2= M3zJfnNCVkeHUh?=
DoTc2-4510 MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzYTWM2OD13LkS1N|cyKM7:TR?= NVHYSG5KW0GQR1XS
LB1047-RCC M4LVWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjUPG5KSzVyPUWuOVU6OzNizszN MXrTRW5ITVJ?
MHH-ES-1 M1jXZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHkfm1KSzVyPUWuOVk6ODdizszN M{LtcnNCVkeHUh?=
NMC-G1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXL3foZYUUN3ME21MlcxOjJ5IN88US=> NFntVlBUSU6JRWK=
SW1710 NGDHcGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF73SoxKSzVyPUWuO|Q4PTFizszN MXnTRW5ITVJ?
YAPC MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnwW21KSzVyPUWuO|YzODFizszN Mn;tV2FPT0WU
22RV1 M{f6bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLW[GdKSzVyPUWuPFAxOTlizszN NX;BPYE4W0GQR1XS
COLO-679 M{XBcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3KTWM2OD13Lki4PVQ5KM7:TR?= M376fnNCVkeHUh?=
TCCSUP NYrqbZI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPCOJB2UUN3ME21Mlk{OjV7IN88US=> M{XDeHNCVkeHUh?=
C2BBe1 NWPNd2t2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXO3Nnl6UUN3ME21Mlk{QTdizszN M{\RRXNCVkeHUh?=
TE-15 NVjOSoZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfPSpZKSzVyPU[uNFY3ODVizszN NY\SVFVnW0GQR1XS
SCLC-21H MlKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTZwMUC4OFMh|ryP NU\LNmhsW0GQR1XS
EoL-1-cell MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1mxO2lEPTB;Nj6xOlU3OyEQvF2= NXnBO5puW0GQR1XS
NKM-1 NHS5bZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zOc2lEPTB;Nj6xOlcyKM7:TR?= NXrPdXY2W0GQR1XS
NCI-H1304 NX;PSIJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTZwMke0Nlgh|ryP NWrENGU5W0GQR1XS
NB6 NV34UoN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XjSWlEPTB;Nj6yPVYzOiEQvF2= MYrTRW5ITVJ?
NALM-6 Mnf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTZwM{OyN{DPxE1? NV:2N2JmW0GQR1XS
NCI-H522 MljkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTZwM{OzNFYh|ryP NGnNR5lUSU6JRWK=
MV-4-11 M4SzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rzXmlEPTB;Nj6zO|A4QSEQvF2= NFvVW4ZUSU6JRWK=
LB2241-RCC NFroV5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTZwM{i2Olch|ryP NXzFOIROW0GQR1XS
NCI-H1417 M2nrVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX24XnVUUUN3ME22MlQxQDR5IN88US=> M1;Xd3NCVkeHUh?=
HT-1197 M3;abWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEj6d4FKSzVyPU[uOVcyOjJizszN NUezSZQ{W0GQR1XS
P30-OHK NESwcGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTZwNkK3O{DPxE1? NGXXSW9USU6JRWK=
ALL-PO MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\p[XdKSzVyPU[uO|E6OTZizszN M4X2[3NCVkeHUh?=
OVCAR-4 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmKzTWM2OD14Lke1OFA2KM7:TR?= NH;mcZNUSU6JRWK=
HCC2157 MlPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTGNJBKSzVyPU[uO|c1PzVizszN NYDqbnpVW0GQR1XS
NCI-H838 NFXu[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPm[JZKSzVyPU[uPVY1QSEQvF2= M4nxenNCVkeHUh?=
NCI-H1299 MkHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTJTlR1UUN3ME22Mlk4ODlizszN M2CxO3NCVkeHUh?=
SW954 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHVTmRiUUN3ME23MlIxODZ6IN88US=> M4HsPXNCVkeHUh?=
NCI-H441 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYG1eY9sUUN3ME23MlM1ODZ3IN88US=> MWHTRW5ITVJ?
SK-MEL-2 NHfPcYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlr1TWM2OD15LkS4N|c{KM7:TR?= NWPKVJlLW0GQR1XS
KARPAS-45 MmroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;uTWM2OD15Lk[1PVI6KM7:TR?= NF;IVY1USU6JRWK=
CAL-54 NGXxeYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PRZWlEPTB;Nz64Nlk4PyEQvF2= M17FVnNCVkeHUh?=
KYSE-180 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUH4OVd3UUN3ME23Mlg5QTRzIN88US=> MlTpV2FPT0WU
NCI-H187 NHLCR5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvCOWVKSzVyPUeuPVU6PDdizszN NWnjTFVmW0GQR1XS
RT-112 NE\NPFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEOxXoJKSzVyPUiuNFk3PzdizszN MV\TRW5ITVJ?
NCI-H1437 NV\uTIx5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPx[mpKSzVyPUiuNFk4QTVizszN NXu1WGt{W0GQR1XS
SNU-449 MnXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX[2XpdQUUN3ME24MlI5Ojd{IN88US=> NEfYO2VUSU6JRWK=
HCC1187 NXHSRmx6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;TfmlEPTB;OD6yPVM6OSEQvF2= M1TXb3NCVkeHUh?=
NCI-H2030 NEW5VJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nsTmlEPTB;OD6zO|cyPCEQvF2= NXf0SFNpW0GQR1XS
HuO-3N1 M1HzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRThwM{e4OFQh|ryP M4[x[3NCVkeHUh?=
COLO-792 NIHz[HFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoT6TWM2OD16LkSxOVI4KM7:TR?= Ml\JV2FPT0WU
MIA-PaCa-2 NYLhcWpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnWzTWM2OD16Lki1OVA5KM7:TR?= NGP6e2hUSU6JRWK=
SK-N-FI Mn;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPZRWJKSzVyPUmuNFQzPSEQvF2= M2LRSnNCVkeHUh?=
MMAC-SF NY\GbGlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXpTWM2OD17LkC5O|UyKM7:TR?= MXjTRW5ITVJ?
NCI-H28 MnrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXftS5QzUUN3ME25MlExPDZ7IN88US=> M4nyR3NCVkeHUh?=
ETK-1 M{T4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nDcGlEPTB;OT6yPVk4PCEQvF2= MmL3V2FPT0WU
NCI-H1993 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HzcmlEPTB;OT60OFI3OSEQvF2= NEXtSXNUSU6JRWK=
no-11 NH61dVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TVdmlEPTB;OT60O|EzKM7:TR?= Ml3CV2FPT0WU
ChaGo-K-1 M{PRXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLPTWM2OD17LkWxOVg{KM7:TR?= M2jvfHNCVkeHUh?=
NCCIT MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTlwNUOxOlkh|ryP M1vWZnNCVkeHUh?=
SAS MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUK4[Y5SUUN3ME2xNE4zPDhizszN M3zqe3NCVkeHUh?=
A673 MmLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;aZXdWUUN3ME2xNE4{PzB2IN88US=> NHm3dI1USU6JRWK=
NCI-H1522 NVjkS29IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTVbXZKSzVyPUGwMlM4ODdizszN NIThZVRUSU6JRWK=
NCI-H810 NHnD[lVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGiyenJKSzVyPUGwMlM6ODdizszN M{XIdHNCVkeHUh?=
IST-MES1 M2DWXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTFyLkS1OlQh|ryP NXXYZ4xnW0GQR1XS
GR-ST M1LmPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfTZnNKSzVyPUGwMlUxOjRizszN NH7JSXpUSU6JRWK=
SUP-T1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHwVXlKSzVyPUGwMlc{OTdizszN MWXTRW5ITVJ?
NB5 M1yxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHIZ2lYUUN3ME2xNE46ODJ{IN88US=> NWP5b|N7W0GQR1XS
MZ1-PC NYf2U3M{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\rcmlEPTB;MUCuPVU4OSEQvF2= M3TuV3NCVkeHUh?=
SK-CO-1 Mme4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLCTpRKSzVyPUGwMlk6OzFizszN Mme3V2FPT0WU
Capan-2 NG[yfZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTFzLkOxPVgh|ryP NIDjfppUSU6JRWK=
697 Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTFzLk[3OVch|ryP MoPTV2FPT0WU
REH M2jidmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXKUo9KSzVyPUGxMlc1PTFizszN MnjBV2FPT0WU
GI-1 NH:4XlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;RTZlKSzVyPUGxMlg3OTVizszN NFTlZ45USU6JRWK=
BB65-RCC NX;5[HJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTF{LkC5NVYh|ryP MWjTRW5ITVJ?
NCI-H1651 NFHufJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLDblVkUUN3ME2xNk4zPDd6IN88US=> MnPnV2FPT0WU
NCI-H1618 MlTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzzeI5KSzVyPUGyMlM6PzZizszN M3zo[3NCVkeHUh?=
NCI-H2081 Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTF{Lk[xOFEh|ryP NV;pTZFnW0GQR1XS
GCIY MlrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnMZ45KSzVyPUGyMlczOTNizszN NWGzc41wW0GQR1XS
NY Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTF|LkC2OFMh|ryP MkXmV2FPT0WU
PANC-03-27 M3LRR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3GOWZ{UUN3ME2xN{4xQDB5IN88US=> NIPLfXBUSU6JRWK=
BHY NYXUVYp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTHd|dKUUN3ME2xN{4zOTJzIN88US=> NH\ZXFNUSU6JRWK=
SK-OV-3 MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP6TWM2OD1zMz6zO|Y{KM7:TR?= NELyclJUSU6JRWK=
5637 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH[2[XVKSzVyPUGzMlc4PTlizszN NIHpVFRUSU6JRWK=
LC-1F NF25NppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYOzOG9EUUN3ME2xOE4xOzV4IN88US=> NHjQc3lUSU6JRWK=
SNB75 Mof5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLwbXFLUUN3ME2xOE4xOzh|IN88US=> MnLNV2FPT0WU
CHP-212 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvvTWM2OD1zND6wOFY1KM7:TR?= NI\0NXVUSU6JRWK=
HT-1376 NIH2TlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrY[mNmUUN3ME2xOE4yOTJ4IN88US=> NIXlRmhUSU6JRWK=
MONO-MAC-6 NWnGbYxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLiNHNKSzVyPUG0MlE2ODJizszN NY\TTYV1W0GQR1XS
CA46 NIXaTHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrRblFKSzVyPUG0MlE5OjdizszN NV7xe5dsW0GQR1XS
SCC-15 NEnCXmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTITWM2OD1zND61OVg{KM7:TR?= NVeyfGoxW0GQR1XS
ATN-1 NIX5ZVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfTTWRsUUN3ME2xOE43PjJ5IN88US=> Mmr5V2FPT0WU
NCI-H2405 NF33SJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojnTWM2OD1zND64NVU4KM7:TR?= NXT0NZlzW0GQR1XS
NCI-H716 NIPOSHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfMc2xXUUN3ME2xOE45PDl|IN88US=> NXXxbHJzW0GQR1XS
SW620 M2iybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml61TWM2OD1zND65NFE1KM7:TR?= M{ewOHNCVkeHUh?=
NCI-H226 NEH6cZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTF2LkmwPFUh|ryP NIfablRUSU6JRWK=
SW962 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2D5UmlEPTB;MUSuPVQ{OiEQvF2= NXPH[FViW0GQR1XS
KYSE-150 M3TvXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTF2Lkm1OUDPxE1? MYnTRW5ITVJ?
OCUB-M M4\oNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXTTWM2OD1zND65PFg{KM7:TR?= NF3MU5hUSU6JRWK=
ES7 NInBPHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIP3TFdKSzVyPUG1MlA6QDRizszN NUjDWG1UW0GQR1XS
SW1463 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHRPGZKSzVyPUG1MlQzOjNizszN M3TRNnNCVkeHUh?=
CAKI-1 M3S1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzvNHBKSzVyPUG1MlU{PDZizszN NF;VRVNUSU6JRWK=
MKN28 MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PkcWlEPTB;MUWuOVQ4QSEQvF2= MY\TRW5ITVJ?
SW13 M2K4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTrdZRQUUN3ME2xOU43OThizszN MmDiV2FPT0WU
A3-KAW M33PXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETHcYpKSzVyPUG1Mlk3QTdizszN NH\VcmdUSU6JRWK=
LU-65 M3zVeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DYVmlEPTB;MUWuPVc3QCEQvF2= NUfCXIprW0GQR1XS
Calu-1 NHPkR3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\jWGtrUUN3ME2xOk4xOzZ6IN88US=> NXrHNm4xW0GQR1XS
ST486 NV\Mc3BYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrJTWM2OD1zNj6wOFMyKM7:TR?= MXXTRW5ITVJ?
BB30-HNC M4DNfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7ubWxRUUN3ME2xOk4yOjR4IN88US=> NF\rdYpUSU6JRWK=
EGI-1 NXLVV2g4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\hbmlEPTB;MU[uOFQ3KM7:TR?= M4TsUHNCVkeHUh?=
SH-4 NHHOTnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTF4LkS3N|Eh|ryP MYjTRW5ITVJ?
MN-60 NIrETJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfsfZBNUUN3ME2xO{4zOjl5IN88US=> MYXTRW5ITVJ?
MPP-89 NVO4[3lnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTF5LkK0OVkh|ryP Mn7aV2FPT0WU
A2780 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXz4XJl7UUN3ME2xO{41OTN7IN88US=> M4PxVXNCVkeHUh?=
Daoy MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXrcotKSzVyPUG3MlQ3QTVizszN MnvQV2FPT0WU
NCI-H2126 NX7od|BsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTF5LkS3O|Eh|ryP NUexWYtyW0GQR1XS
NCI-H1563 NWSyfI1wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEO5WIpKSzVyPUG3MlQ6OTdizszN Mn[4V2FPT0WU
8-MG-BA NWexWmpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XRWGlEPTB;MUeuOlY1QCEQvF2= MnXtV2FPT0WU
786-0 NV[2PGZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLzTWM2OD1zNz64N|U{KM7:TR?= MkjuV2FPT0WU
AM-38 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nDT2lEPTB;MUeuPVMxPiEQvF2= NUPsR2lDW0GQR1XS
COLO-824 M1j0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHVRVY4UUN3ME2xPE41PDN4IN88US=> NXzYOYV6W0GQR1XS
SK-MEL-30 NIDqSW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrmbol4UUN3ME2xPE42ODh{IN88US=> MXnTRW5ITVJ?
CESS Ml7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvU[I1KSzVyPUG4Mlc3ODlizszN MlK4V2FPT0WU
BL-70 NETS[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmD0TWM2OD1zOD64NVU3KM7:TR?= NYXMWnZiW0GQR1XS
NCI-H2170 Mly2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7SNXdrUUN3ME2xPE46OTd7IN88US=> NEHEcYlUSU6JRWK=
HT-3 NVn0RpM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{joUGlEPTB;MUiuPVg{KM7:TR?= NELMdHdUSU6JRWK=
BOKU NVn4eoFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1mzXmlEPTB;MUmuNFM5OSEQvF2= MWfTRW5ITVJ?
HPAF-II NE\oW3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEC3SGZKSzVyPUG5MlMxOTVizszN Mn\iV2FPT0WU
KGN NFf0TpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moj0TWM2OD1zOT60O|Y2KM7:TR?= MXrTRW5ITVJ?
MC-CAR MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTjTWM2OD1zOT62N|E{KM7:TR?= M2[0U3NCVkeHUh?=
BHT-101 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmS0TWM2OD1zOT63O|ch|ryP NU\renhlW0GQR1XS
SW1783 MlzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPyWnpKSzVyPUG5Mlc5ODZizszN MYPTRW5ITVJ?
KP-N-YN MmP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fKNWlEPTB;MkCuNFI3OiEQvF2= MWHTRW5ITVJ?
LU-165 NWHmO5BQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILRWYZKSzVyPUKwMlU2PzFizszN NVfucIhbW0GQR1XS
GOTO MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnL5TWM2OD1{MD62OFUyKM7:TR?= NXPHfFl4W0GQR1XS
EFM-19 NHzROnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnVT4pKSzVyPUKxMlA4OTZizszN NILNdGpUSU6JRWK=
CTV-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHLTWM2OD1{MT6xNFU1KM7:TR?= NXnPfplQW0GQR1XS
HEL NYHGWZV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTJzLkSyNVYh|ryP M1;wXHNCVkeHUh?=
SNU-C2B NXn1R483T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDabFBKSzVyPUKxMlQzPiEQvF2= MYnTRW5ITVJ?
ECC4 M4nRRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlv5TWM2OD1{MT63NFch|ryP M{HGVnNCVkeHUh?=
NEC8 M2TY[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETSOFJKSzVyPUKxMlg{PjhizszN MUTTRW5ITVJ?
KMOE-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYH6eFlCUUN3ME2yNU45QTJzIN88US=> MkTTV2FPT0WU
NCI-H524 NGTSOm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXC[oljUUN3ME2yNk4xQDB6IN88US=> M{Lh[XNCVkeHUh?=
WSU-NHL NEP0OIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M365TGlEPTB;MkKuNVU4PyEQvF2= NI\hb|RUSU6JRWK=
SF126 M4LE[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXGTWM2OD1{Mj6yOFY6KM7:TR?= MVvTRW5ITVJ?
HOP-92 M2LNPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTJ{LkOxOlch|ryP MmjzV2FPT0WU
CTB-1 MkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rpNmlEPTB;MkKuOFY4PyEQvF2= M2T0SHNCVkeHUh?=
KYSE-270 M1TZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XkOmlEPTB;MkKuPVM2PyEQvF2= M1rGPXNCVkeHUh?=
SK-MEL-24 NVPvUG1rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[1WWRnUUN3ME2yN{4yQDdizszN Ml76V2FPT0WU
Calu-3 NWDQT2FJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV64UFZbUUN3ME2yN{4zOTJ6IN88US=> MkjSV2FPT0WU
GAMG MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVniWlB2UUN3ME2yN{4zOzZ5IN88US=> NETUdZRUSU6JRWK=
SW1573 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3QfIRKSzVyPUKzMlc1OTVizszN NF7BV3RUSU6JRWK=
MHH-NB-11 MlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17IRWlEPTB;MkSuNFE6PCEQvF2= MUHTRW5ITVJ?
TK10 MljzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFu2XVJKSzVyPUK0MlUxOTNizszN NXHyfnAzW0GQR1XS
LB373-MEL-D M{XIW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPucpFKSzVyPUK0MlYxPjRizszN MW\TRW5ITVJ?
KALS-1 M13mOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jUWWlEPTB;MkSuO|MzPyEQvF2= NUXPe4RPW0GQR1XS
HUTU-80 Mk\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PoS2lEPTB;MkWuPFA{OiEQvF2= MV7TRW5ITVJ?
HuP-T3 M4HlU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzhOlVoUUN3ME2yOk4yPjd2IN88US=> MYLTRW5ITVJ?
OE19 NX7ld4ZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLZTWM2OD1{Nj6yNVU{KM7:TR?= M4m1OHNCVkeHUh?=
J82 M2ThPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWP2VGpvUUN3ME2yOk4zPDdzIN88US=> MXTTRW5ITVJ?
DU-4475 NVXHU|hwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rGOGlEPTB;Mk[uN|gyQSEQvF2= MVjTRW5ITVJ?
DMS-53 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4j1N2lEPTB;Mk[uOVE{QCEQvF2= NGnWZYpUSU6JRWK=
COLO-741 M4\EN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzsOY9KSzVyPUK2Mlg{PDRizszN M{ftSnNCVkeHUh?=
SW48 NHXxd4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\4XHhKSzVyPUK2Mlg5OiEQvF2= M{\Ic3NCVkeHUh?=
IGR-1 NHnoco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;4TWM2OD1{Nj65N|M1KM7:TR?= MUfTRW5ITVJ?
639-V MmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTJ5LkCyOFUh|ryP MV3TRW5ITVJ?
LK-2 M4Wxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGP2VJpKSzVyPUK3MlQyPDFizszN NYXhW2d5W0GQR1XS
NCI-H2347 Mo\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXruXmJJUUN3ME2yO{46Pjl7IN88US=> MX7TRW5ITVJ?
NCI-H2228 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LDNWlEPTB;MkiuNFkxPSEQvF2= NFvxRmFUSU6JRWK=
LS-123 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1T6eWlEPTB;MkiuNVI3OiEQvF2= MlXUV2FPT0WU
U031 MlvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\2emlEPTB;MkiuNlUzKM7:TR?= MWTTRW5ITVJ?
NCI-H1792 M4nwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTJ6LkS3NlEh|ryP MWHTRW5ITVJ?
NCI-H2087 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTPTWM2OD1{OD63OVUzKM7:TR?= NIX3blNUSU6JRWK=
NCI-H2342 M4nnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTYOHNKSzVyPUK5MlUzODhizszN NYLRRmc4W0GQR1XS
SW626 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDITWM2OD1{OT63OVYh|ryP M2jYNHNCVkeHUh?=
LB2518-MEL M4i0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzKO5FlUUN3ME2yPU45OTVizszN NIjjTJZUSU6JRWK=
RXF393 NWm5SVQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTEPHBKSzVyPUOwMlA6PTJizszN MVHTRW5ITVJ?
LC4-1 M4DhcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnf5TWM2OD1|MD6zNFkzKM7:TR?= M{fzW3NCVkeHUh?=
NCI-H1694 NEPub5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTNyLk[2NlQh|ryP NXmwZoFSW0GQR1XS
K5 MmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HrVGlEPTB;M{CuPVcxOiEQvF2= NUDyVphWW0GQR1XS
HDLM-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLTcYhKSzVyPUOwMlk4OjVizszN NUDGOnJoW0GQR1XS
BCPAP MoroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{i0c2lEPTB;M{GuPFM4QSEQvF2= NUD5eXNlW0GQR1XS
BC-3 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTN{LkG0NFMh|ryP NFXMe|dUSU6JRWK=
LB996-RCC M2Dvcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTN{LkKzOVgh|ryP MmX3V2FPT0WU
NCI-H2009 NWS2U21XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPqXpg6UUN3ME2zNk41QThzIN88US=> M1PYOXNCVkeHUh?=
HTC-C3 NWL0OoZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1KyT2lEPTB;M{OuO|UyQSEQvF2= MW\TRW5ITVJ?
LAMA-84 MorFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHMTWM2OD1|ND60OFA4KM7:TR?= NV\rT2dbW0GQR1XS
CCRF-CEM Mlq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrLTWM2OD1|ND61O|E2KM7:TR?= NI\iO|VUSU6JRWK=
AN3-CA MliyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;BTWM2OD1|NT6wOVY5KM7:TR?= NUjyU3c5W0GQR1XS
NCI-H1734 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3uyTGlEPTB;M{WuNlU3OSEQvF2= NFrsXFNUSU6JRWK=
Ca-Ski MnTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPnc5loUUN3ME2zOU41OTBzIN88US=> NYXXRlhrW0GQR1XS
U-266 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTN3Lk[xNVQh|ryP NG\tclBUSU6JRWK=
SBC-5 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PlN2lEPTB;M{WuO|c5OSEQvF2= MofoV2FPT0WU
GT3TKB MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\3emlEPTB;M{euNVE2KM7:TR?= NHfXb4pUSU6JRWK=
MDA-MB-175-VII NIf5UG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M375dmlEPTB;M{euNlI1QCEQvF2= MmjIV2FPT0WU
PFSK-1 Moe1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDiTWM2OD1|Nz6yOFM2KM7:TR?= MnmyV2FPT0WU
IMR-5 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYD6OXpWUUN3ME2zO{4zPDh5IN88US=> NYGzOXZKW0GQR1XS
Daudi MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\tSWlKSzVyPUO3MlM2QTdizszN NUDvUFBNW0GQR1XS
A498 M2r3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDUTWM2OD1|Nz63NlE5KM7:TR?= MVnTRW5ITVJ?
SCC-4 M2e1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jqPGlEPTB;M{euO|g1OyEQvF2= M{THTHNCVkeHUh?=
COLO-680N MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;tSFBKSzVyPUO4MlI5QDVizszN M3fVZ3NCVkeHUh?=
SK-MES-1 MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTN6LkOyNVUh|ryP MX;TRW5ITVJ?
SR NHz4WZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTobodqUUN3ME2zPE42PDl3IN88US=> NVn5Omh[W0GQR1XS
LNCaP-Clone-FGC NYfG[IFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DPOmlEPTB;M{iuOVY{PyEQvF2= MonwV2FPT0WU
SK-HEP-1 MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIP1OVFKSzVyPUO4Mlc5OjJizszN NYX5Oo1DW0GQR1XS
BPH-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmqxTWM2OD1|OD64N|I6KM7:TR?= NXq3botnW0GQR1XS
NCI-H1755 NUfQ[ZQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHtTWM2OD1|OT61PFE4KM7:TR?= Mm\aV2FPT0WU
LXF-289 Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnnW|NKSzVyPUO5MlgxQDRizszN NEPTS4JUSU6JRWK=
SW1088 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzrTWM2OD12MD6yNVA4KM7:TR?= MUTTRW5ITVJ?
MOLT-4 NHPwVYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTPWlZKSzVyPUSwMlI6ODFizszN NF7lc|hUSU6JRWK=
AsPC-1 NEHlU5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LhRmlEPTB;NECuOFU5OyEQvF2= MVHTRW5ITVJ?
HOP-62 MoXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HzTGlEPTB;NECuOlU3QCEQvF2= MXzTRW5ITVJ?
A172 M1nNVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1OxV2lEPTB;NECuPFUyOSEQvF2= MnrZV2FPT0WU
SN12C MnHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTRyLkmzPFUh|ryP MmLtV2FPT0WU
MDA-MB-231 NWHBO3pKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXTTWM2OD12MD65PFk5KM7:TR?= MXnTRW5ITVJ?
RPMI-2650 NHXqWHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrVTWM2OD12MT6xOVk{KM7:TR?= MV;TRW5ITVJ?
KYSE-140 NEnTeIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPEeFBKSzVyPUSxMlgyOjNizszN MnvMV2FPT0WU
KINGS-1 M3;QUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTR{LkS2PVch|ryP NXPxbotqW0GQR1XS
HSC-3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3lTWM2OD12Mj62OlYyKM7:TR?= MlrxV2FPT0WU
PC-14 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\zOJhKUUN3ME20N{4yQDh{IN88US=> NFTweHlUSU6JRWK=
COR-L105 MkX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLrTWM2OD12Mz62OVAzKM7:TR?= MYLTRW5ITVJ?
BE-13 M1HLV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PFb2lEPTB;NESuNlM4OSEQvF2= M1r6eXNCVkeHUh?=
NCI-H661 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTR2LkK5OVgh|ryP NFzodnJUSU6JRWK=
IST-MEL1 MlLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWX2b3czUUN3ME20OE4{PTl7IN88US=> NF7ke49USU6JRWK=
HCC1806 M1Tze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;3bW9KSzVyPUS0MlU5PzNizszN MmK0V2FPT0WU
COLO-800 Ml72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUT3OJZjUUN3ME20OE45PDV|IN88US=> Mn:zV2FPT0WU
IST-SL2 Mn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3I[nhKSzVyPUS1MlEzPDdizszN MlrGV2FPT0WU
8305C NXTWb21QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrUN49KSzVyPUS1MlMxQSEQvF2= MkP6V2FPT0WU
UACC-62 NW\teJV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPFOItKSzVyPUS2MlI5PzVizszN MVTTRW5ITVJ?
COR-L23 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\4cnZKSzVyPUS3MlE6QSEQvF2= MmDUV2FPT0WU
EFE-184 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1GxVGlEPTB;NEeuN|g5KM7:TR?= MoD2V2FPT0WU
DMS-114 NXvkR3hsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTR5LkSxOFkh|ryP MWTTRW5ITVJ?
KYSE-520 NUjBUWlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfLc|FKSzVyPUS4MlU{OTVizszN MV\TRW5ITVJ?
SNG-M NHu2XYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jmOmlEPTB;NEmuOFM1KM7:TR?= NHfHXpRUSU6JRWK=
A2058 MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTR7LkS4PFUh|ryP NHf0cmZUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]

Protocol

Kinase Assay:[1]
+ Expand

Protein kinase biochemical assays:

Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.
Cell Research:[1]
+ Expand
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3 days
  • Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
  • Formulation: 25 mM tartaric acid
  • Dosages: 25 mg / kg and 75 mg / kg
  • Administration: Orally administrated at once-daily oral dose for 14 days
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
30% PEG 400+0.5% Tween 80+5% Propylene glycol
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development, Inc.|Astellas Pharma Inc April 2014 Phase 2
NCT02546544 Active, not recruiting Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2
NCT01533246 Completed Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer National Cancer Institute (NCI) February 2012 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • Answer:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

Related Antibodies

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Tags: buy Linsitinib (OSI-906) | Linsitinib (OSI-906) supplier | purchase Linsitinib (OSI-906) | Linsitinib (OSI-906) cost | Linsitinib (OSI-906) manufacturer | order Linsitinib (OSI-906) | Linsitinib (OSI-906) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID